PLEASANTON, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Thoratec Corporation a world leader in products to treat cardiovascular disease, said today that D. Keith Grossman, president and chief executive officer, will provide updates on the company at two upcoming investment banking conferences.
The company will be appearing at the Lazard Life Sciences Conference at 8:30 a.m., Eastern Standard Time (5:30 a.m. Pacific Standard Time), on Wednesday, November 30. The presentation will be available through the conference website at http://www.wsw.com/webcast/lz2/thor/
The company will also be appearing at the First Albany Capital Third Annual Growth Conference at 8 a.m., Eastern Standard Time (5 a.m. Pacific Standard Time), on Tuesday, December 6. That presentation can be accessed via the conference web site at http://www.wsw.com/webcast/lz2/thor/
Thoratec Corporation is a world leader in hemodynamic restoration therapy -- developing products to treat cardiovascular disease. The company’s product line includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (left ventricular assist system) with nearly 10,000 devices implanted in patients suffering from heart failure. Thoratec’s HeartMate LVAS is the first and to date only FDA-approved device for Destination Therapy, or the permanent support of late-stage heart failure patients who are not eligible for heart transplantation. Thoratec’s product line also includes the Vectra(R) vascular access graft (VAG) for patients undergoing hemodialysis. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com
Thoratec Corporation
CONTACT: Investor - Cynthia Lucchese, Senior Vice President, ChiefFinancial Officer of Thoratec Corporation, +1-925-847-8600, or Neal Rosenof Kalt Rosen & Company for Thoratec Corporation, +1-415-397-2686; or Media- Jennifer Chan of FischerHealth, Inc. for Thoratec Corporation,+1-310-577-7870, ext. 164, jchan@fischerhealth.com
